The short answer: pregnancy and breastfeeding are different, and the active ingredient matters
If the question is whether a medicine should be used to produce weight loss during pregnancy, the answer is no. Pregnancy is not a time for an intentional calorie deficit or active weight reduction. Current labeling for semaglutide, tirzepatide and liraglutide, as well as oral medicines such as phentermine/topiramate, naltrexone/bupropion and orlistat, directs discontinuation when pregnancy is recognized or lists pregnancy as a contraindication [1, 2, 3, 4, 5, 6, 7]. This does not mean that obesity or excess weight should go unmonitored. It means the goal changes to adequate nutrition, an appropriate pattern of gestational weight gain, safe movement, and management of diabetes, hypertension or other conditions with the obstetric and medical team [1].
Breastfeeding is more nuanced. Medicines differ, and even formulations of the same active ingredient can differ. Some oral combinations are explicitly not recommended, while newer evidence has found very low or unmeasurable milk concentrations after certain injections; however, information about long-term infant outcomes and milk production remains limited [2, 3, 5, 6, 8, 9, 10]. Do not start or restart treatment on your own, and do not automatically stop breastfeeding because of one dose. A sound decision considers the exact ingredient and formulation, the reason for treatment, the infant's age and prematurity, the extent of breastfeeding, maternal nutrition and available alternatives [8, 9, 10].
Why are weight-loss medicines stopped during pregnancy?
The main reason is not simply that these medicines are new; the therapeutic objective itself changes. Placental development, fetal growth, expanding blood volume and maternal tissue changes require reliable energy, protein, iron, folate and micronutrient intake. Medicines that suppress appetite, delay gastric emptying or reduce fat absorption can make those needs harder to meet, especially when nausea, vomiting or low intake is already present. Guidance therefore separates obesity treatment before conception from weight and nutrition care during pregnancy [1, 2, 3, 4, 7].
A second reason is that human safety information remains incomplete for most weight-management medicines. Labels describe reproductive signals from animal studies for several agents and established human risks for particular components. The clearest example is topiramate in the phentermine/topiramate combination: early pregnancy exposure is associated with an increased risk of congenital malformations, including oral clefts, which is why pregnancy testing is recommended before treatment and monthly during use [6]. Early human GLP-1 data offer some reassurance after unintended exposure, but they are not sufficient to establish these medicines as safe pregnancy treatments [11].
If you are planning conception, see weight-loss medicines before pregnancy: stopping timelines and preconception care for ingredient-specific washout periods. This page focuses on an established pregnancy and breastfeeding. Do not apply one internet timeline to every medicine; their persistence differs, and some products require gradual withdrawal to avoid problems such as seizures [2, 6].
If pregnancy starts while you are taking medicine: what to do now
First, withhold further doses of the weight-loss medicine until you promptly contact the prescriber and your obstetric clinician. Gather the product and active-ingredient names, strength and dose, date of the last dose, first day of the last menstrual period, and every other medicine or supplement used. If the product is phentermine/topiramate, urgent review is especially important because of topiramate's established risk, but do not improvise withdrawal from a high dose: its label requires gradual discontinuation in some circumstances to reduce seizure risk [6]. Semaglutide, tirzepatide, liraglutide and naltrexone/bupropion weight-management products are discontinued when pregnancy is recognized according to their labels [2, 3, 4, 5].
Exposure does not automatically mean harm occurred, and it is not enough by itself to determine a pregnancy outcome. A prospective observational study of first-trimester GLP-1 exposure did not find a clear increase in major birth defects compared with relevant reference groups, but the sample was limited and the researchers emphasized the need for larger studies [11]. That is balanced reassurance, not permission to continue treatment. Your clinician can interpret the exposure timing, ingredient and coexisting conditions, then arrange appropriate pregnancy follow-up without unnecessary scans or tests.
Seek urgent assessment for persistent severe vomiting, inability to keep fluids down, dizziness or fainting, severe abdominal pain, vaginal bleeding, or symptoms of low blood glucose when diabetes medicines are involved. Dehydration, bleeding and severe pain need evaluation because of the symptoms themselves, not merely because a weight medicine was taken [1, 2, 3].
Decisions by medicine group: injections are not the same as tablets
The GLP-1 class and dual GIP/GLP-1 agonists include ingredients such as semaglutide, liraglutide and tirzepatide. These medicines differ in persistence, formulation, and whether they are used for diabetes or weight management. Weight-management products are discontinued during pregnancy [2, 3, 4]. For their general mechanisms, monitoring and adverse effects, the GLP-1 medicines: a practical guide covers the broader treatment questions without repeating the pregnancy detail here [2, 3, 4].
Tablets are not one interchangeable group either. Phentermine/topiramate is contraindicated in pregnancy and has a safety program and pregnancy-testing requirements because of topiramate risk. Breastfeeding is not recommended during its use because both components enter human milk and infant effects may occur [6]. Naltrexone/bupropion is stopped when pregnancy is recognized; its components and metabolites enter milk, so lactation needs clinician review rather than automatic use as a slimming tablet [5]. Orlistat is contraindicated in pregnancy and can also reduce absorption of fat-soluble vitamins. Its presence in human milk is unknown, requiring caution and individual review during lactation [7].
The brand name alone is therefore not enough. The same ingredient may be marketed for diabetes or weight management, and semaglutide is available as injections and as tablets containing a distinct absorption enhancer. Record the exact active ingredient and formulation, and do not switch products as though one were a safe substitute. If the medicine was prescribed for glucose control rather than weight alone, the diabetes and obstetric clinicians need to establish an alternative or monitoring plan; untreated hyperglycemia can itself harm the mother and pregnancy [1, 2].
During breastfeeding: what is known and what remains uncertain?
Newer evidence makes the answer more precise than a simple yes or no. In a small study of eight mothers using injectable semaglutide, the medicine was not measurable in milk samples. Their infants were older than newborns and mixed-fed, so the study cannot by itself answer questions about an exclusively breastfed newborn or long-term treatment [8, 12]. LactMed distinguishes injectable semaglutide from tablets containing the absorption enhancer SNAC: the oral formulation is not recommended during breastfeeding because of possible enhancer transfer and accumulation, while an injection may be discussed clinically with attention to maternal nutrition and infant growth [2, 8].
For tirzepatide, recent single-dose data found no measurable medicine in most milk samples and only a very small amount in the remainder. The study did not establish repeated-dose exposure or provide sufficient information about infant effects or milk production. The label therefore asks clinicians to balance breastfeeding benefits, maternal clinical need and possible infant effects, while LactMed advises particular caution for newborn or preterm infants [3, 9]. For liraglutide, adequate direct human milk data are absent. Its molecular size suggests low transfer and poor infant absorption, but caution is still appropriate [4, 10].
Drug transfer is not the only question. Could appetite suppression leave the mother eating or drinking too little? Marked appetite loss, vomiting or dehydration could compromise recovery and nutrition and might affect milk supply. A lactation decision therefore considers feeding pattern, infant growth and the mother's ability to nourish herself, not only a milk concentration [8, 9, 12].
When can treatment be reconsidered after birth?
There is no single postpartum week that suits everyone. The body is recovering from pregnancy and birth while sleep, hydration, intake and milk production change rapidly. Before restarting medicine, a clinician asks: Is breastfeeding exclusive, mixed or complete? Was the infant born at term or prematurely? Is growth satisfactory? Does the mother have type 2 diabetes, hypertension or sleep apnoea that creates a more urgent medical reason for treatment, or is the goal rapid cosmetic weight loss? How adequate are food, protein, iron, fluids and emotional wellbeing? [1, 3, 8, 9, 10].
If breastfeeding continues, decisions are generally more conservative with a newborn or preterm infant and whenever growth or milk supply is a concern. Some tablets are explicitly not recommended during lactation, whereas discussion of certain injections is possible only after an individualized review that acknowledges evidence gaps. Once breastfeeding has ended, one part of the decision disappears, but treatment is not automatically suitable. Medical conditions, contraindications, interactions, contraception and plans for another pregnancy still require review [2, 3, 5, 6, 8, 9].
Strong hunger during breastfeeding is normal and is not a failure of willpower. I am breastfeeding, hungry all the time and want to lose weight. What can I do safely? explains meal structure, hydration and satiety without drifting into medicine selection. A safe start is usually a realistic eating routine, attention to recovery and sleep where possible, and then a calm medication assessment rather than a race against the scale [1].
Contraception and fertility: do not wait for regular periods to ask
Ovulation can return before the first postpartum period, and weight loss or improved insulin sensitivity may change ovulatory regularity in people with PCOS. Irregular periods are therefore not contraception, and breastfeeding itself is reliable only under specific clinical criteria and for a limited interval. If pregnancy is possible, discuss an appropriate method before starting a weight medicine and tell the prescriber about any near-term pregnancy plan [1, 3].
Tirzepatide has an important practical issue. Because it delays gastric emptying, its label advises people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting treatment and for four weeks after each dose escalation [3]. This exact instruction does not automatically apply to every GLP-1 medicine, so do not transfer directions from one drug to another. Phentermine/topiramate requires a pregnancy test before initiation and monthly testing with effective contraception because topiramate-associated malformations can begin early, before pregnancy is recognized [6].
If periods are irregular or PCOS symptoms are present, PCOS and weight: understanding the link and what helps covers the broader diagnostic and treatment pathway. Do not interpret a more regular or irregular cycle as proof that pregnancy cannot occur. Record the contraceptive method and any severe vomiting or diarrhea that might impair pill absorption, then discuss it with the obstetric clinician or pharmacist. A good plan connects weight goals with reproductive plans instead of treating them separately [3, 6].
Your next step: a coordinated review rather than a rushed decision
Before the visit, photograph the medicine package or record the active ingredient, dose, last dose date, prescribing reason, and every other medicine or supplement. Note whether pregnancy is confirmed or possible, gestational age if known, whether breastfeeding is exclusive or mixed, the infant's age, and any prematurity. Also record vomiting, diarrhea, dizziness, food and fluid intake, and any concern about milk supply or infant growth. These details matter more than the scale number alone [2, 3, 5, 6, 8, 9].
A structured review separates three questions: Must the medicine stop now because of pregnancy? Is a condition such as diabetes present that needs a pregnancy-compatible alternative instead of simple withdrawal? Is postpartum restart suitable now, or is deferral preferable because of breastfeeding, nutrition or another pregnancy plan? Coordination may involve obstetric, diabetes or internal-medicine, pediatric and weight-management clinicians. Do not rely on a friend's experience, the word injection or natural, or an old social post, because lactation evidence and product labels change [1, 2, 3, 8, 9].
At the clinic, assessment is meant to organize risks and alternatives without promising a particular amount of weight loss or pressuring anyone to stop breastfeeding. If you need to discuss weight medicine during pregnancy or lactation, you can request a weight-management consultation and bring the treatment list and pregnancy or feeding details. For bleeding, severe pain, fainting, marked dehydration or low blood glucose, seek urgent care rather than waiting for a routine appointment [1, 2, 3].
